---
document_datetime: 2025-02-24 15:24:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kavigale-epar-all-authorised-presentations_en.pdf
document_name: kavigale-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6977152
conversion_datetime: 2025-12-30 22:53:21.922381
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form             | Route of Administration            | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------|------------------------------------|-----------------------|---------------------------|-------------|
| EU/1/24/1900/001 | KAVIGALE          | 300 mg     | Solution for injection/infusion | Intramuscular use, Intravenous use | vial (glass)          | 2 ml (150 mg/ml)          | 1 vial      |